Business Combinations (Purchase Price Allocation and Other Disclosures) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended					3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012 ABH	Mar. 31, 2011 ABH	Jun. 28, 2011 ABH	Mar. 31, 2012 FerroKin BioSciences Inc	Apr. 02, 2012 FerroKin BioSciences Inc	Apr. 19, 2012 Pervasis Therapeutics Inc	Mar. 31, 2012 Pervasis Therapeutics Inc
Business Acquisition [Line Items]
Contingent consideration payable - maximum						$ 225.0			$ 169.5
Cash consideration paid					739.6		94.5	2.5
Post acquisition revenues included in consolidated statement of income			48.8	0
Net income	238.4	211.3
Post acquisition pre-tax losses included in consolidated statement of income			9.6	0
Amortization of intangible assets			9.8	0
Integration and acquisition costs	$ 5.3	$ (6.4)	$ 3.7	$ 0		$ 1.6
Percentage of voting interests acquired					100.00%		100.00%